RxDoctor Payments Data

Daniel Ofori, MD

Ophthalmology · Memphis, TNNPI 1619388691

Payments from drug & device makers

$2,305in general payments, 2019–2025

Across 18 payments — averaging $128.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$125
  • Kala Pharmaceuticals, Inc.$120
  • Lensar, Inc.$64
  • NEW World Medical,inc.$22
  • Sun Pharmaceutical Industries Inc.$19
  • plus $13 from 1 others

What the payments were for

  • Travel & lodging$1,47764%
  • Food & beverage$82836%

General payments by program year

19
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,305 in reported general payments places this provider in the 55th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$264,255
Medicare patients
609
Services billed
2,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast30$35,471
RestasisCyclosporine37$32,798
Cyclosporine32$28,478
RocklatanNetarsudil Mesylat/Latanoprost32$16,163
Restasis MultidoseCyclosporine23$15,473
LumiganBimatoprost21$11,752
Latanoprost465$8,575
SimbrinzaBrinzolamide/Brimonidine Tart25$8,321
Loteprednol Etabonate51$8,246
Brimonidine Tartrate97$8,143
Fluorometholone73$5,054
MoxifloxacinMoxifloxacin Hcl234$4,652
Travoprost33$3,201
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat172$3,123
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$2,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose, Lumigan$125$60,02381 claims
AlconSimbrinza$1,941$8,32125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →